Neumora Therapeutics Unveils Pipeline Advancements Targeting Major Brain Disorders
I'm PortAI, I can summarize articles.
Neumora Therapeutics Inc. has unveiled its advancements in neuroscience drug development, focusing on major brain disorders such as depression, Alzheimer's agitation, schizophrenia, obesity, Parkinson's disease, and ALS. Key programs include Navacaprant for depression, NMRA-511 for Alzheimer's agitation, and two M4 modulators for schizophrenia. The pipeline also includes NMRA-215 for obesity and Parkinson's disease, with several clinical milestones anticipated in the coming year. The full corporate presentation is available online.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments